Future therapies in hormone-refractory prostate cancer

Matthew R. Smith; Joel B. Nelson; Robert S. DiPaola; Michael A. Carducci; Ian M. Thompson

doi:10.1016/j.urology.2005.03.043

Future therapies in hormone-refractory prostate cancer

Matthew R. Smith, Joel B. Nelson, Robert S. DiPaola, Michael A. Carducci, Ian M. Thompson

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).

Original language	English (US)
Pages (from-to)	9-17
Number of pages	9
Journal	Urology
Volume	65
Issue number	5 SUPPL.
DOIs	https://doi.org/10.1016/j.urology.2005.03.043
State	Published - May 2005
Externally published	Yes

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.urology.2005.03.043

Cite this

@article{64000f1950d0458eb75de3f9b54ca137,

title = "Future therapies in hormone-refractory prostate cancer",

abstract = "Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).",

author = "Smith, {Matthew R.} and Nelson, {Joel B.} and DiPaola, {Robert S.} and Carducci, {Michael A.} and Thompson, {Ian M.}",

year = "2005",

month = may,

doi = "10.1016/j.urology.2005.03.043",

language = "English (US)",

volume = "65",

pages = "9--17",

journal = "Urology",

issn = "0090-4295",

publisher = "Elsevier Inc.",

number = "5 SUPPL.",

}

TY - JOUR

T1 - Future therapies in hormone-refractory prostate cancer

AU - Smith, Matthew R.

AU - Nelson, Joel B.

AU - DiPaola, Robert S.

AU - Carducci, Michael A.

AU - Thompson, Ian M.

PY - 2005/5

Y1 - 2005/5

N2 - Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).

AB - Hormone-refractory prostate cancer (HRPC) remains true to its name: it is largely refractory to attempts to delay its progression. Although the number of men presenting with metastatic prostate cancer has decreased significantly over the last several years, the death rate for those men is essentially unchanged. To alter the currently inevitable progression of HRPC to death, new targets and new therapies are needed. This article reviews investigational therapies directed against standard targets (eg, the hypothalamic-pituitary-gonadal axis) as well as novel targets (eg, the endothelin axis).

UR - http://www.scopus.com/inward/record.url?scp=18244404560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244404560&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2005.03.043

DO - 10.1016/j.urology.2005.03.043

M3 - Article

C2 - 15885273

AN - SCOPUS:18244404560

SN - 0090-4295

VL - 65

SP - 9

EP - 17

JO - Urology

JF - Urology

IS - 5 SUPPL.

ER -

Future therapies in hormone-refractory prostate cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this